protocolSection identificationModule nctId: NCT06288373, orgStudyIdInfo id: NACI-CERV-003, briefTitle: Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2031-03-01, completionDateStruct date: 2031-03-01, studyFirstPostDateStruct date: 2024-03-01, lastUpdatePostDateStruct date: 2024-03-01, sponsorCollaboratorsModule leadSponsor name: Tongji Hospital, class: OTHER, collaborators name: Southwest Hospital, China, collaborators name: Women Hospital, School of Medicine, Zhejiang University, collaborators name: Anhui Provincial Cancer Hospital, collaborators name: Sichuan Cancer Hospital and Research Institute, collaborators name: Qilu Hospital of Shandong University, collaborators name: Beijing Friendship Hospital, collaborators name: Tianjin Medical University General Hospital, collaborators name: West China Second University Hospital, collaborators name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, collaborators name: Xiangya Hospital of Central South University, collaborators name: Gansu Provincial Maternal and Child Health Care Hospital, collaborators name: Zhejiang Cancer Hospital, collaborators name: Shengjing Hospital, descriptionModule briefSummary: It is a prospective, open-label, randomized, controlled phase II/III clinical trial in which patients with PD-L1-positive FIGO stage IB3, IIA2 and IIB（tumors \>4 cm in diameter）will be enrolled and randomly divided into the neoadjuvant chemoimmunotherapy plus surgery group and the CCRT group., conditionsModule conditions: Cervical Cancer, conditions: Locally Advanced Cervical Cancer, conditions: Concurrent Chemoradiotherapy, conditions: Neoadjuvant Chemoimmunotherapy, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 440, type: ESTIMATED, armsInterventionsModule interventions name: Camrelizumab, interventions name: Cisplatin, interventions name: Nab paclitaxel, interventions name: Radical surgery, interventions name: external beam radiation therapy (EBRT) + brachytherapy, interventions name: Cisplatin, outcomesModule primaryOutcomes measure: Progression-free survival, PFS, primaryOutcomes measure: Objective Response Rate, ORR, secondaryOutcomes measure: Overall survival, OS, secondaryOutcomes measure: Proportion of patients undergoing radical surgery, secondaryOutcomes measure: Pathologic Complete Response, secondaryOutcomes measure: The surgical complication rate, secondaryOutcomes measure: Safety and toleraty, secondaryOutcomes measure: Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Function Score, secondaryOutcomes measure: Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24) Score, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, city: Wuhan, state: Hubei, zip: 430030, country: China, contacts name: Kezhen Li, role: CONTACT, phone: 086-027-8362, email: tjkeke@126.com, contacts name: Jing Chen, role: CONTACT, phone: 086-027-8362, email: chenjing3223@126.com, contacts name: Kezhen Li, role: PRINCIPAL_INVESTIGATOR, contacts name: Gang Chen, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False